**Supplementary Figure 1.** Flow chart of patient disposition. Abbreviations: BID, twice daily; PD, progressive disease; QD, once daily.

Dose escalation

3 + 3 design, 10 cohorts

n = 63

Cohort expansion

Cobimetinib 60 mg QD +

Vemurafenib 720 mg BID

n = 27

Cohort expansion

Cobimetinib 60 mg QD +

Vemurafenib 960 mg BID

n = 39

All treated patients (safety population)

n = 129

Follow-up: Vemurafenib   
monotherapy–PD

n = 66

Follow-up: BRAF inhibitor–naive

n = 63

Discontinued study

n = 65

Reason, n (%)

* PD, 56 (86.2)
* Adverse event, 2 (3.1)
* Death, 1 (1.5)
* Withdrew consent, 2 (3.2)
* Physician decision, 3 (4.6)
* Other, 1 (1.5)

Discontinued study

n = 58

Reason, n (%)

* PD, 39 (62.9)
* Adverse event, 8 (12.9)
* Death, 0
* Physician decision, 1 (1.6)
* Withdrawal by patient, 0
* Other, 7 (11.3)
* Lost to follow-up, 1 (1.6)